In vitro and in vivo evaluation of 2-aminoalkanol and 1,2-alkanediamine derivatives against *Strongyloides venezuelensis*

Ana L. Legarda-Ceballos\(^1\), Julio López-Abán\(^1\)*, Esther del Olmo\(^2\), Ricardo Escarcena\(^2\), Luis A. Bustos\(^2,3\), Jose Rojas-Caraballo\(^1,4,5\), Belén Vicente\(^1\), Pedro Fernández-Soto\(^1\), Arturo San Feliciano\(^2\) and Antonio Muro\(^1\)

**Abstract**

**Background:** Strongyloidiasis is a parasitic disease widely present in tropical and subtropical areas. *Strongyloides stercoralis* represents the main species that infects human beings. Ivermectin is the current drug of choice; however, issues related with treatment failure in patients with diabetes or infected with T-lymphotropic virus-1 make the identification of new molecules for alternative treatment a priority. In the present study, the activity of sphingosine-related aminoalcohol and diamine were evaluated against *Strongyloides venezuelensis* third-stage larva (L3) cultures and experimental infections in mice.

**Methods:** The efficacy of each compound against L3 was assessed using both XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay and microscopic observation with concentrations ranging from 1 to 350 \(\mu\)M. Cytotoxicity was evaluated using J774.2 macrophage cell line and XTT assay. Lethal concentration 50 \((LC_{50})\), selectivity index (SI) and structure-activity relationships were established. The activity compounds 4 (2-(ethylamino) hexadecan-1-ol), 6 (2-(butylamino) hexadecan-1-ol), 17 (2-(butylamino) hexadecan-1-ol), 17 (2-(butylamino) hexadecan-1-ol) and 18 (2-(butylamino) hexadecan-1-ol) were further assessed against experimental *S. venezuelensis* infections in CD1 mice measuring reductions in the numbers of parthenogenetic females and egg passed in faeces. Mice were infected with 3,000 L3 and treated with 20 mg/kg/day for five days.

**Results:** In the screening study of 15 aminoalcohols [lauryl \((n = 9)\); palmityl \((n = 13)\); stearyl \((n = 15)\) and alcohol derivatives], the presence of a palmitol chain was associated with the highest efficacy against L3 \((LC_{50} 31.9–39.1 \mu\)M). Alkylation of the 2-amino group with medium size fragments as ethyl or n-butyl showed the best larvicidal activity. The dialkylation did not improve efficacy. Aminoalcohols 4 and 6 showed the highest SI (1.5 and 1.6, respectively). With respect to diamine derivative compounds, a chain size of sixteen carbon atoms (palmitoloyl chain, \(n = 13\)), and the alkylation of the 2-amino group with medium-sized fragments, were associated with the highest lethal activities. The presence of carbamoyl group in diamines 17 and 18 yielded high SI (1.7 and 1.4, respectively). Infected mice treated with aminoalcohol 6 showed reduction in parthenogenetic females (59 %) and eggs in faeces (51 %).

**Conclusions:** These results support the potentiality of aminoalcohol and diamine sphingosine-related compounds as suitable prototypes for developing new promising drugs against strongyloidiasis.

**Keywords:** Strongyloidiasis, Treatment, Alkaneaminoalcohol, Alkanediamine, Anthelmintics
Background
Strongyloidiasis is a parasitic disease caused by nematodes of the genus *Strongyloides*, which are widely present in tropical and subtropical areas with climate suitable for the survival of larval stages of the species of this genus. The main species causing the disease in the human beings is *Strongyloides stercoralis* and it is estimated that 30 to 100 million people are infected around the world [1]. Strongyloidiasis is also classified as a Neglected Tropical Disease, according to the World Health Organization [2, 3]. This parasite has a complex life-cycle: larvae penetrate the skin of the host and migrate through the bloodstream to the lungs, where they enter into the alveolar spaces, ascending to the respiratory tree, the trachea, the pharynx and finally migrate back through the oesophagus and stomach into the intestine where they reach maturity [4–6]. Parthenogenetic females inhabit the mucosa of the small intestine where the eggs are laid. The rhabditiform larvae (L1) are eliminated together with faeces and develop over a few days in temperate and humid environment to infective third-stage filariform larvae (L3). Minimally symptomatic chronic infection and cutaneous, respiratory or gastrointestinal signs are observed in patients. *Strongyloides stercoralis* has also the ability to cause systemic disseminated infection and hyperinfection syndrome in immunocompromised humans. In most of these cases the outcome of the disease is fatal [7, 8].

Ivermectin is an effective well-tolerated drug against strongyloidiasis, reaching cure rates of 93.1–96.8 % with one single dose administration [9]. On the other hand, treatment failure has been observed in patients co-infected with *S. stercoralis* and human T-lymphotropic virus-1 (HTLV-1) [10] and concomitance with diabetes [11]. Albendazole, mebendazole and thiabendazole given in multiple doses are also used for the treatment of strongyloidiasis but their efficacy and tolerability is not as efficient as ivermectin [12, 13]. The concern about decreased efficacy in human nematodosis and the possibility of acquired-resistance in treatments of human nematodes is increasing [14, 15]. Additionally, rare population genotypes have shown encephalopathy when treated against *Loa loa* infections with ivermectin [16] making the discovery of new alternative nematicidal drugs a high priority challenge.

Long chain aminocloahols and diamine derivatives are sphingosine-related compounds considered as key molecules for designing alternative drugs to the current treatment of infectious diseases. Biocidal activity of these compounds has been reported against bacteria such as *Mycobacterium tuberculosis* [17], protozoans such as *Plasmodium* spp. [18], *Leishmania* spp. [19], *Trypanosoma brucei* [20], *T. cruzi* [21], *Trichomonas vaginalis*, *Giardia lamblia* [22], fungi [23] and helminths such as *Schistosoma mansoni* [24] or the nematode *Caenorhabditis elegans* [25].

Methods

Animals and ethics statement
Animal procedures complied with the European Union (Di 2010/63/CE) and the Spanish (L32/2007, L6/2013, RD53/2013) regulations on animal experimentation. The University of Salamanca’s Ethics Committee also approved the procedures that were used in this study (Protocol: 48531). Male Wistar rats weighing 80–120 g from the Animal Experimentation facilities of the University of Salamanca (Registration No. PAE/SA/001) and male Specific Pathogen Free (SPF) CD1 mice (Charles River, Barcelona, Spain) weighing 25–30 g were used for the maintenance of *S. venezuelensis* life-cycle and for in vivo experiments in standard conditions. Size of groups was calculated by power analysis [27] using “size.fdr” package for R and following the 3Rs recommendations [28].

Maintaining *Strongyloides venezuelensis* life-cycle and parasitological techniques

The *S. venezuelensis* strain from the Department of Parasitology (University of Minas Gerais, Belo Horizonte, Brazil) was maintained at the University of Salamanca (biosecurity protocol No. 15/019) by serial in vivo passages in Wistar rats. The infective third-stage larvae (L3) of *S. venezuelensis* were obtained from 3 to 4 day-old vermiculite cultures of faeces from infected rats using a Baermann apparatus. L3 were decontaminated according to the methodology previously reported by Martins et al. [29]. Freshly obtained L3 were washed six times, for twenty minutes each, with distilled water containing 100 IU/ml penicillin, 0.1 mg/ml streptomycin and 0.8 mg/ml fluconazole. Absence of bacterial contamination was confirmed by culturing larvae from each batch on a Petri dish containing blood agar at 28 °C during 24 h. Wistar rats were infected with 6,000 L3 in 0.5 ml phosphate buffered saline (PBS) using a 23-gauge needle syringe to maintain the life-cycle. To perform faecal egg counts, mice were placed on grids over clean moist absorbent paper and allowed to defecate. Individual faecal...
samples were collected, conserved in a 10% v/v formalin buffered solution and counted in triplicate under a microscope using McMaster technique and egg per gram were reported. The upper half of the small intestine was removed after euthanasia (pentobarbital 100 mg/kg), minced and placed in a sedimentation cup wrapped by 8 layers of gauze in PBS for 2 h at 37 °C. The parthenogenetic females were then collected from the sediment and their number recorded.

Drugs and sample preparation

The procedures for the synthesis of 2-aminoalkan-1-ol (type I; compounds 1–15) and alkane 1,2-diamine (type II; compounds 16–25) derivatives, which are structurally related to sphingosine, were previously reported (Fig. 1) [17, 19, 20, 30]. Fifteen aminoalcohol and ten diamine derivatives were synthesized. Compounds were solubilized in dimethyl sulfoxide (DMSO) and appropriate dilutions were made to perform assays. Edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) was obtained from R. Berchtold (Biochemisches Labor, Bern, Switzerland) and used as reference for in vitro studies. Ivermectin was purchased from Sigma (St Louis, MO, USA) and used as a reference drug for the in vivo treatment of strongyloidiasis.

Cytotoxicity assessment in mouse macrophage cultures

The J774.2 mouse-derived peritoneal macrophage cell line was used to assess the cytotoxicity of the compounds. Macrophages were grown and serial successive in vitro passages were performed according to the methodology previously described by Rojas-Caraballo et al. [31]. To study the cytotoxicity of each compound, 200 µl of a suspension containing 1 × 10⁵ cells/ml were added onto 96 well flat-bottom microplates, allowed to adhere to the surface of the plate for 2 h at 37 °C, 5% CO₂ and then exposed to the compounds for 72 h at the following concentrations: 0.1; 0.5; 3.3; 15.0; 35.0, and 70.0 µM. Each concentration was assayed at least in triplicate in three independent experiments. Cytotoxicity was evaluated based on the colorimetric 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay. After the treatment, 50 µl of XTT solution were added to each individual well and plates were incubated for 24 h at 37 °C. The absorbance of the plate was then measured at 492 nm using an ELISA-plate reader (Anthos Labtec Instruments, Wals, Austria). Results were expressed as the percentage of macrophages remaining alive after each treatment. Untreated and DMSO-treated macrophages were used as controls. Each concentration was assayed in triplicate in three independent experiments and the LC₅₀ value for each compound was calculated by sigmoidal regression analysis [32].

Efficacy and structure-activity study relationship of compounds against third-stage larva cultures

A hundred decontaminated L3 in water were added to 96-well flat bottom microplates. Each compound was added at 1, 10, 35, 70 and 350 µM and then incubated during 72 h at 28 °C in triplicate and in a minimum of three independent experiments. Larval viability was quantified both by using the colorimetric XTT assay as described above and by monitoring larval motility at 24, 48 and 72 h post-treatment. Larval movement was recorded after stimulation with direct natural light for 2 min using an inverted microscope (CK2, Olympus, Tokio, Japan) and a video recorder (AM423 camera and DinoCapture 2.0 software, Dino-Lite digital microscope, Naarden, Holland). Larvae were considered dead when no movement was detected for at least two minutes of detailed examination. As controls, L3 were incubated in water or treated with edelfosine in a range of 1–350 µM. Results were expressed as the concentration of each compound able to inhibit 50% of total larvae movement (LC₅₀), calculated by sigmoidal regression analysis [32]. Selectivity Index (SI) was calculated as the ratio between the LC₅₀ value of each compound in macrophage culture and the LC₅₀ in L3 cultures to compare the efficacy and toxicity of each compound. Potency relative to edelfosine (Pₑₑₑₐₑₐₑₐₑₑ) was calculated as the ratio between edelfosine-LC₅₀ and LC₅₀ of each compound. Edelfosine, a sphingosine-related compound, was used based on the low toxicity and high in vitro activity against helminths observed in previous experiments in our laboratory [33] The influence of the side-chain size, the substitution of the 2-amino group, and the presence of a free hydroxyl function or a benzyl ether on the activity of each compound were studied in compounds of type I.

![Fig. 1 General structures for aminoalcohol derivatives (type I, compounds 1–15) and diamine derivatives (type II, compounds 16–25)](image-url)
The influence of the substituents on the 1-amino group and the presence of a tert-butoxycarbonyl (Boc) protecting group on the 2-amino group have also been examined in type II compounds.

Assessment of efficacy against *S. venezuelensis* infection in mice

Those compounds showing the best activity against L3 in the screening test (aminoalcohols 4 and 6, and diamines 17 and 18) were tested in *S. venezuelensis* experimental infections of mice. For this purpose, we used a total of 64 male CD1 mice randomly distributed in groups of eight animals. We performed two independent experiments with four groups each: infection control, infected and treated with ivermectin and two groups infected and treated with their respective selected compound. In the first experiment, the aminoalcohols 4 and 6 were tested and in the second experiment the diamines 17 and 18 were tested. All mice were subcutaneously infected with 3,000 L3 of *S. venezuelensis* prior to drug treatment. Ivermectin was orally administered with a single standard dose of 0.2 mg/kg on day 5 post-infection (p.i.). Aminoalcohols and diamines were orally administered with a dose of 20 mg/kg/day at the day of infection and during the next five days to let reaching therapeutic concentration after day 5 p.i. Doses were determined on the basis of the cytotoxicity and previous experience in our laboratory with using sphingosine-related compounds [23, 34]. The number of parasitic females in the gut on day 7 p.i. and the number of eggs released in the faeces during the experiment were quantified to evaluate the efficacy of the treatment.

Statistical analysis

The results were expressed as the mean and the standard error of the mean (SEM). Normality of data distribution was assessed by the non-parametric Kolmogorov-Smirnov test and the homogeneity of variance was tested by the Barret test. Significant differences between groups were found using one-way ANOVA followed by Tukey’s honest significance test. All statistical analyses were considered significant at a *P*-value < 0.05. All analyses and graphics were performed with Prism 5 (GraphPad Software, San Diego, CA) for Mac.

Results

Efficacy of aminoalcohols and diamines against *S. venezuelensis* L3

Concerning the in vitro activity against *S. venezuelensis* larvae of the aminoalcohol derivatives (compounds 1–15 in Table 1), compounds 4 and 6 showed the highest larvicidal activity (LC$_{50}$ = 35.1 ± 0.1 and 31.9 ± 0.5 μM, respectively), that is 1.4 and 1.5 times, respectively, more potent than edelfosine (LC$_{50}$ = 49.6 ± 0.5 μM) but less than ivermectin (LC$_{50}$ = 0.46 ± 0.1 μM) after 72 h of culture. Compounds 4 and 6 had cytotoxicity values of LC$_{50}$ = 52.0 ± 5.3 μM and LC$_{50}$ = 52.0 ± 4.1 μM, respectively, which were also less toxic than edelfosine or ivermectin for macrophages (LC$_{50}$ = 40.7 ± 7.1 and 1.1 ± 0.1 μM, respectively). The SI for edelfosine and ivermectin were 0.8 and 2.4, respectively, while for compounds 4 and 6 the SI were 1.5 and 1.6, respectively, meaning double selectivity (Table 1; Additional file 1: Video S1, Additional file 2: Video S2 and Additional file 3: Video S3 for compound 4 and Additional file 4: Video S4, Additional file 5: Video S5 and Additional file 6: Video S6 for compound 6). Compounds 14, 9, 11 and 1 also elicited good activity with SI values ranging from 0.7 to 0.5 compared to edelfosine activity. Unfortunately all of these were more toxic than edelfosine.

Ten alkane-1,2-diamines were also tested, compounds 16–25 (Table 2). Compounds 17, 18, 23 and 24 were more potent than edelfosine, with relative potency values of 1.2, 1.2, 1.2 and 1.4, respectively. Compounds 23 and 24 were more toxic than edelfosine, while SIs of compounds 17 and 18 were 1.7 and 1.4, respectively (Table 2: Additional file 7: Video S7, Additional file 8: Video S8 and Additional file 9: Video S9 for compound 17 and Additional file 10: Video S10, Additional file 11: Video S11 and Additional file 12: Video S12 for compound 18). Compounds 25, 16, 20 and 22 have also shown good activity, ranging from 0.7 to 0.5 compared to edelfosine activity. Compound 16 cytotoxicity was similar to edelfosine while the other three were more toxic.

Compounds, 4, 6, 17 and 18, which reached the highest SI values, seemed to act in a dose- and time-dependent manner, since larval viability was progressively inhibited to completion as dose and time increased. As a consequence of the global consideration of SI values, larval viability measured by XTT and motility examination, the four compounds were selected for evaluation of their in vivo efficacy in infected mice.

Efficacy of aminoalcohols and diamines against *S. venezuelensis* experimental infections in mice

The in vivo anti-*Strongyloides* efficacy of compounds 4, 6, 17 and 18 is summarized in Table 3 and Fig. 2. Aminoalcohol 6 induced parthenogenetic female burden reduction of 59 % (Fig. 2a) and significant reductions in egg numbers in faeces on days 6 and 7 p.i. ranging from 35 to 51 %, respectively (Table 3) compared to infection controls. Administration of diamine 18 resulted in reduction in the number of eggs in faeces on day 7 p.i. (50 %; Table 3) and moderate but not significant reduction of parthenogenetic females in the gut (25 %; Fig. 2b). Despite aminoalcohol 4 and diamine 17 inducing a moderate reduction of eggs in faeces (45 and 21 %, respectively) they failed to reduce female burdens on day 7.
Table 1: In vitro efficacy and selectivity measured by XTT of alkane aminoalcohol derivatives against *S. venezuelensis* third-stage larvae (L3)

| Compound | R<sup>1</sup> | R<sup>2</sup> | R<sup>3</sup> | n | Efficacy against L3 LC<sub>50</sub> (μM) Mean ± SEM | Potency relative to edelfosine (P<sub>EDEL</sub>) | Cytotoxicity SI<sup>b</sup> LC<sub>50</sub> (μM) Mean ± SEM |
|----------|--------------|--------------|--------------|---|---------------------------------|-------------------|---------------------------------|
| 1        | H            | H            | H            | 9 | 97.8 ± 10.6                     | 0.5               | 17.4 ± 0.4                      | 0.2                           |
| 2        | H            | H            | H            | 13| 348.4 ± 1.5                     | 0.1               | nt                              | –                             |
| 3        | H            | H            | H            | 15| 239.3 ± 7.9                     | 0.2               | nt                              | –                             |
| 4        | H            | H            | Et           | 13| 35.1 ± 0.1<sup>c</sup>          | 1.4               | 520 ± 5.3                       | 1.5                           |
| 5        | H            | H            | Bu           | 9 | 297.6 ± 5.4                     | 0.1               | 37.9 ± 1.9                      | 0.1                           |
| 6        | H            | H            | Bu           | 13| 31.9 ± 0.5<sup>d</sup>          | 1.5               | 520 ± 4.1                       | 1.6                           |
| 7        | H            | H            | Bu           | 15| 293.3 ± 2.6                     | 0.1               | 100 ± 1.5                       | <0.1                          |
| 8        | H            | H            | Hex          | 15| 122.7 ± 6.4                     | 0.4               | 43.2 ± 0.9                      | 0.4                           |
| 9        | H            | H            | Hex          | 13| 84.2 ± 4.3                      | 0.5               | 10.9 ± 1.3                      | 0.1                           |
| 10       | H            | H            | Hex          | 15| 112.5 ± 5.3                     | 0.4               | 542 ± 0.9                       | 0.5                           |
| 11       | H            | Et           | Et           | 13| 90.0 ± 5.7                      | 0.2               | 22 ± 2.2                        | <0.1                          |
| 12       | H            | Bu           | Bu           | 9 | 169.0 ± 9.2                     | 0.2               | 63.7 ± 1.2                      | 0.4                           |
| 13       | H            | Bu           | Bu           | 13| 192.1 ± 7.7                     | 0.2               | nt                              | –                             |
| 14       | Bn           | H            | H            | 13| 67.6 ± 6.3                      | 0.7               | 30.2 ± 0.3                      | 0.4                           |
| 15       | Bn           | H            | Bu           | 13| 232.0 ± 4.5                     | 0.2               | nt                              | –                             |
| Edelfosine|              |              |              |   | 49.6 ± 0.5                      | 1.0               | 40.7 ± 7.1                      | 0.8                           |

Abbreviations: Bn Benzyl, Bu Butyl, Et Ethyl, nt not tested, SEM standard error of the mean, R<sup>1</sup> substituent on the hydroxyl group; R<sup>2</sup> and R<sup>3</sup> substituents on the amine group

<sup>a</sup>Potency relative to edelfosine (P<sub>EDEL</sub>) = Compound-LC<sub>50</sub> against L3 / Edelfosine-LC<sub>50</sub> against L3

<sup>b</sup>Selectivity index (SI) = Compound-LC<sub>50</sub> to macrophages/Compound-LC<sub>50</sub> against L3

<sup>c</sup>Significant increase in P<sub>EDEL</sub> compared to edelfosine (ANOVA: F<sub>(15, 62)</sub> = 413.82, P < 0.001; HDS P = 0.008)

<sup>d</sup>Significant increase in P<sub>EDEL</sub> compared to edelfosine (ANOVA: F<sub>(15, 62)</sub> = 413.82, P < 0.001; HDS P = 0.002)

---

Table 2: In vitro efficacy and selectivity measured by XTT of alkane diamines derivatives against *S. venezuelensis* third-stage larvae (L3)

| Compound | R<sup>1</sup> | R<sup>2</sup> | R<sup>3</sup> | n | Efficacy against L3 LC<sub>50</sub> (μM) Mean ± SEM | Potency relative to edelfosine (P<sub>EDEL</sub>) | Cytotoxicity SI<sup>b</sup> LC<sub>50</sub> (μM) Mean ± SEM |
|----------|--------------|--------------|--------------|---|---------------------------------|-------------------|---------------------------------|
| 16       | H            | H            | H            | 13| 75.0 ± 4.1                      | 0.6               | 40.1 ± 0.4                      | 0.5                           |
| 17       | H            | H            | Boc          | 9 | 39.0 ± 2.9<sup>e</sup>          | 1.2               | 66.6 ± 2.2                      | 1.7                           |
| 18       | H            | H            | Boc          | 13| 39.1 ± 4.7<sup>e</sup>          | 1.2               | 56.2 ± 3.3                      | 1.4                           |
| 19       | H            | H            | Boc          | 15| 45.7 ± 9.2                      | 1.0               | 36.8 ± 2.8                      | 0.8                           |
| 20       | H            | Et           | H            | 13| 95.4 ± 1.5                      | 0.5               | 10.5 ± 1.4                      | 0.1                           |
| 21       | H            | Bu           | H            | 13| 148.3 ± 3.3                     | 0.3               | 15.5 ± 1.2                      | 0.1                           |
| 22       | H            | Hex          | H            | 13| 83.6 ± 3.1                      | 0.5               | 5.2 ± 0.5                       | 0.0                           |
| 23       | H            | Hex          | Boc          | 13| 38.9 ± 4.6<sup>e</sup>          | 1.2               | 49 ± 0.8                        | 0.1                           |
| 24       | Et           | Et           | H            | 13| 33.4 ± 0.7<sup>d</sup>          | 1.4               | 13.2 ± 1.7                      | 0.3                           |
| 25       | Hex          | Hex          | Boc          | 13| 67.8 ± 7.1                      | 0.7               | 7.6 ± 0.6                       | 0.1                           |
| Edelfosine|              |              |              |   | 49.6 ± 0.5                      | 1.0               | 40.7 ± 7.1                      | 0.8                           |

Abbreviations: Bn Benzyl, Bu Butyl, Et Ethyl, Hex hexyl, Boc tert-butoxycarbonyl, SEM standard error of the mean; R<sup>1</sup> and R<sup>2</sup> substituents on the amine at position C-2; R<sup>3</sup> substituents on the amine at position C-3

<sup>a</sup>Potency relative to edelfosine (P<sub>EDEL</sub>) = Compound-LC<sub>50</sub> against L3 / Edelfosine-LC<sub>50</sub> against L3

<sup>b</sup>Selectivity index (SI) = Compound-LC<sub>50</sub> to macrophages/Compound-LC<sub>50</sub> against L3

<sup>c</sup>Significant increase in P<sub>EDEL</sub> compared to edelfosine (ANOVA: F<sub>(10, 72)</sub> = 216.85, P < 0.001; HDS P = 0.001)

<sup>d</sup>Significant increase in P<sub>EDEL</sub> compared to edelfosine (ANOVA: F<sub>(10, 72)</sub> = 216.85, P < 0.001; HDS P = 0.002)
Table 3 Reduction in egg per gram of faeces (EPGF) in mice infected with 3,000 S. venezuelensis L3 after treatment with aminoalcohol derivatives 4 and 6 and diamine derivatives 17 and 18 for five days at a dose of 20 mg/kg, and ivermectin 0.2 mg/kg

| Groups            | EPGF on day 5 (Mean ± SEM) | Reduction (%) | EPGF on day 6 (Mean ± SEM) | Reduction (%) | HDS | EPGF on day 7 (Mean ± SEM) | Reduction (%) | P     | HDS     |
|-------------------|---------------------------|---------------|---------------------------|---------------|-----|---------------------------|---------------|-------|---------|
| **Experiment 1**  |                           |               |                           |               |     |                           |               |       |         |
| Infected          | 2,020 ± 430               | –             | 24,800 ± 5,210            | –             |     | 12,5150 ± 9,200           | –             |       |         |
| Ivermectin        | 5,240 ± 580               | nr            | 330 ± 110                 | 99<sup>a</sup> | <0.001 | 0 ± 0                    | 100<sup>a</sup> | <0.001 |         |
| Aminoalcohol 4     | 3,830 ± 570               | nr            | 20,220 ± 3,080            | 18            | 0.274 | 68,980 ± 12,810           | 45<sup>a</sup> | <0.001 |         |
| Aminoalcohol 6     | 4,720 ± 900               | nr            | 16,160 ± 1970             | 35<sup>a</sup> | 0.044 | 61,680 ± 1,917            | 51<sup>a</sup> | <0.001 |         |
| ANOVA             | F<sub>3, 28</sub> = 3.28; |               | F<sub>3, 28</sub> = 13.42;|               |     | F<sub>3, 28</sub> = 45.31;|               |       |         |
|                   | P = 0.051                 |               | P < 0.001                 |               |     | P < 0.001                 |               |       |         |
| **Experiment 2**  |                           |               |                           |               |     |                           |               |       |         |
| Infected          | 3,190 ± 300               | –             | 11,060 ± 1,710            | –             |     | 82,820 ± 5,364            | –             |       |         |
| Ivermectin        | 2,950 ± 300               | 8             | 160 ± 90                  | 99<sup>a</sup> | <0.001 | 80 ± 50                   | 100<sup>a</sup> | <0.001 |         |
| Diamine 17        | 2,715 ± 410               | 15            | 10,890 ± 1,200            | 2             | 0.912 | 65,520 ± 7,037            | 21<sup>a</sup> | 0.025 |         |
| Diamine 18        | 3,410 ± 520               | nr            | 8,110 ± 430               | 27            | 0.060 | 41,450 ± 5,382            | 50<sup>a</sup> | <0.001 |         |
| ANOVA             | F<sub>3, 28</sub> = 0.59; |               | F<sub>3, 28</sub> = 23.03;|               |     | F<sub>3, 28</sub> = 47.94;|               |       |         |
|                   | P = 0.625                 |               | P < 0.001                 |               |     | P < 0.001                 |               |       |         |

Abbreviations: HDS Tukey’s honest significance test, nr no reduction, SEM standard error of the mean
<sup>a</sup>Significant reduction compared to infected control group

Fig. 2 Number of parthenogenetic females on day 7 post-infection. a Mice treated with 20 mg/kg of aminoalcohols 4 and 6 (ANOVA F<sub>3, 28</sub> = 62.93, P < 0.001). b Mice treated with 20 mg/kg of diamines 17 and 18 (ANOVA F<sub>3, 28</sub> = 48.03, P < 0.001). Worms were recovered from the intestine of mice infected with 3,000 S. venezuelensis L3 and treated during five days. Each point represents data from individual mice and horizontal bars indicate the means; stars indicate significant reduction of worm recovery compared to infected control.
p.i. (Table 3; Fig. 2). During the experiments, all mice used (64/64) remained alive and there was not evidence of any symptoms of severe pain, excessive distress, suffering or an impending death in any of the animals. Daily oral administration of each compound (20 mg/kg/day) and ivermectin (0.2 mg/kg) were well tolerated by animals in all experiments.

**Discussion**

To the best of our knowledge, this study represents the first insight into therapeutic use of alkane aminoalcohols and diamines against a nematode such as *S. venezuelensis*. Synthetic new compounds developed for cancer or organ transplantation are very attractive and untapped resources for the development of new drugs for neglected diseases such as the strongyloidiasis. Long chain-aminoalcohols and diamines are sphingosine-derivatives that have been considered as target molecules for development of new drugs showing cytotoxicity against neoplastic cells [35], and possessing anti-inflammatory properties [34, 36] and ability to kill infectious agents [18, 24, 37]. However, they have never been used against nematodes such as *Strongyloides* spp. These compounds have structural resemblances to anticancer alkylphospholipids with anthelmintic activity against *S. mansoni* and *S. venezuelensis* [38]. Therefore, we used the alkylphospholipid edelfosine as control for in vitro experiments.

We have studied the structure-activity relationships in both type I and type II compounds. We found that aminoalcohols 4 and 6 with a palmitoyl chain (n-hexadecan-1-ol) and the diamines 17 and 18 with chains of lauroyl (n-dodeca-1-ol) and palmitoyl, respectively, showed a more potent activity against *S. venezuelensis* L3, with low cytotoxicity for mammal macrophages and high selectivity indices (SIs) indicating their potential efficacy. Concerning aminoalcohol derivatives (compounds 1–15) the following comparisons of results can be performed. Examination of the substituents of the 2-amino group indicated the preference for a small- (ethyl) to medium- (butyl) sized alkyl group in the secondary amine, as seen in derivatives 4 and 6, suggesting a decrease in the activity with increase in substituent size increase, compound 9 activity. Interestingly, compound 6 (2-n-butylamino-hexadecan-1-ol) was found to be less toxic and had a better SI than the reference drug edelfosine. Compound 6 was also the most potent and selective compound among the aminoalcohols tested. Transformation of the secondary amines 4 and 6 into their respective tertiary analogues 11 and 13 led to a fair reduction of activity. Regarding the 1,2-alkanediamines 16–25 (Table 2), the most potent compound against larvae was the diamine 24, a compound with a primary amine at position C-2 and a tertiary one at C-1; unfortunately, it showed a high cytotoxicity. Compounds 17, 18 and 23, the three Boc-protected diamines, showed similar efficacy against L3; the last one was highly toxic, and the other two had SIs of 1.7 and 1.4, respectively. Compounds 17 and 18 only differed in the size of the chain, with respective n-values of 9 and 13; in this case, a small size chain gave less toxicity. In summary, based on the ten alkanediamines tested, it can be concluded that there is a preference for compounds with a Boc-protecting group attached to the 2-amino group in the in vitro activity assays.

Inhibition of the viability of L3 induced by compound 6 increased in a dose- and time-dependent manner, demonstrated using both XTT technique and motility records. Lipophilic diamine and aminoalcohol derivatives containing chains with 13 carbon atoms demonstrate activity against *T. cruzi* trypomastigotes [24], indicating they possess the best range of activity. It seems that the 16-carbon chain length could be involved in the drug’s increased solubility, absorption and harmful action, leading to the dead of the larvae [39]. We observed that only aminoalcohol 6, containing an alkyl chain with a 16-carbon atom chain and a butyl radical, displayed efficacy against *S. venezuelensis* infection in mice. Although this activity was less effective than ivermectin, the choice drug for strongyloidiasis treatment, our data indicate that oral treatment with aminoalcohol 6 significantly decreases both, the recovered adult parthenogenetic females in the small intestine and the number of eggs per gram of faeces. Aminoalcohol 6 has also demonstrated the highest activity against three *T. cruzi* strains in cultures [21].

Alkylphospholipids, aminoalcohols and diamines have the ability to interact with membrane lipids, allowing their penetration into the parasite where they may disturb cell metabolism and integrity [24]. The pro-apoptotic mechanism was also described in edelfosine [38, 40] and in long chain aminoalcohols [41]. Further studies should be conducted to determine the mechanisms of action. Despite aminoalcohol 6 did not exhibit activity comparable to ivermectin, combinations with current drugs may result in useful synergistic interactions.

**Conclusions**

In conclusion, we have reported the strongyloidicidal activity of two series of sphingosine-related compounds, 15 aminoalkanols and 10 alkanediamines, against *S. venezuelensis* using L3 cultures and a strongyloidiasis murine model to search for promising lead compounds that can be optimized to improve their potency and selectivity. This preliminary study introduces aminoalcohol 6 as a suitable prototype for the design of new anti-*Strongyloides* drugs. However, further in vivo studies need to be conducted in order to confirm the outcomes achieved and its utility in therapy against strongyloidiasis and other geohelminthiases.
Additional files

**Additional file 1: Video S1.** Motility in *S. venezuelensis* L3 treated with aminoalcohol 4 at 24 h post treatment under optical microscope. (MP4 6713 kb)

**Additional file 2: Video S2.** Motility in *S. venezuelensis* L3 treated with aminoalcohol 4 at 48 h post treatment under optical microscope. (MP4 6623 kb)

**Additional file 3: Video S3.** Motility in *S. venezuelensis* L3 treated with aminoalcohol 4 at 72 h post treatment under optical microscope. (MP4 6562 kb)

**Additional file 4: Video S4.** Motility in *S. venezuelensis* L3 treated with aminoalcohol 6 at 24 h post treatment under optical microscope. (MP4 6999 kb)

**Additional file 5: Video S5.** Motility in *S. venezuelensis* L3 treated with aminoalcohol 6 at 48 h post treatment under optical microscope. (MP4 687 mb)

**Additional file 6: Video S6.** Motility in *S. venezuelensis* L3 treated with aminoalcohol 6 at 72 h post treatment under optical microscope. (MP4 6772 kb)

**Additional file 7: Video S7.** Motility in *S. venezuelensis* L3 treated with diamine 17 at 24 h post treatment under optical microscope. (MP4 7218 kb)

**Additional file 8: Video S8.** Motility in *S. venezuelensis* L3 treated with diamine 17 at 48 h post treatment under optical microscope. (MP4 7202 kb)

**Additional file 9: Video S9.** Motility in *S. venezuelensis* L3 treated with diamine 17 at 72 h post treatment under optical microscope. (MP4 7327 kb)

**Additional file 10: Video S10.** Motility in *S. venezuelensis* L3 treated with diamine 18 at 24 h post treatment under optical microscope. (MP4 7206 kb)

**Additional file 11: Video S11.** Motility in *S. venezuelensis* L3 treated with diamine 18 at 48 h post treatment under optical microscope. (MP4 7297 kb)

**Additional file 12: Video S12.** Motility in *S. venezuelensis* L3 treated with diamine 18 at 72 h post treatment under optical microscope. (MP4 7365 kb)

Abbreviations

ANOVA, analysis of variance; Boc, tert-butoxycarbonyl protecting group; HDS, Tukey’s honest significance test; HTLV-1, Human T-lymphotropic virus-1; L1, first-stage larva or rhabditiform larva; L3 third-stage larva or filariform larva; LC50, lethal concentration 50%; P<0.05, Tukey’s honest significance test; EDL, Equal Distribution Limit; L2, second-stage larva or rhabditoid; MDM, monocyte-derived macrophage; L3, third-stage larva or filariform larva; L4, fourth-stage larva or second-stage juvenile; SI, selectivity index; XTT, 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide.

Acknowledgements

We want to thank J.J. Muñoz Quijano for video production and edition, and F.J. Burguillo Muñoz, University of Salamanca for the statistical analysis support. We also acknowledge the support of Manasa Bhatta (Emory University) for the English edition and the editorial help for the style correction.

Funding

Financial support came from Proyectos Integrados IBSAL (IBY15/00003; Salamanca, Spain), ISCIPI-FIS (ICETEX VI PN de I+D+i 2013–2016 FEDER: RD12/2011/00020) and CIETUS-University of Salamanca. LAB was supported by International Fellowship USAL-Banco Santander and Human Capital Program-CONICYT, Chile.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Authors’ contributions

EO and ASF designed the compounds of the study. RE and LAB synthesized and characterized the compounds tested. JL-A and AM designed the in vitro and in vivo experiments. ALL-C, JR-C, BV and PF-S performed the biological assays. EO, JL-A, ALL-C, JR-C, BV, PF-S, ASF and AM analysed and interpreted the data. JL-A, EO, JR-C and ALL-C drafted the first manuscript. ASF and AM critically revised the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The University of Salamanca’s Ethics Committee approved the procedures involving animals used in this study (Protocol: 48531).

Author details

1Parasite and Molecular Immunology Laboratory, Tropical Disease Research Centre, University of Salamanca (IBSAL-CIETUS), Avda. Licenciado Méndez Nieto s/n, 37007 Salamanca, Spain. 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy (IBSAL-CIETUS), University of Salamanca, 37007 Salamanca, Spain. 3Present Address: Departamento de Ciencias Farmacéuticas, Facultad de Ciencias, Universidad Católica del Norte, Antofagasta, Chile. 4Present Address: Centro de Investigación en Salud para el Trópico (CIST), Carretera Troncal del Caribe, Sector Mamatoco, Santa Marta, Magdalena, Colombia. 5Present Address: Facultad de Medicina, Universidad Cooperativa de Colombia, Carretera Troncal del Caribe, Sector Mamatoco, Santa Marta, Magdalena, Colombia.

Received: 24 January 2016 Accepted: 16 June 2016

Published online: 28 June 2016

References

1. Schar F, Trostorf U, Gardina F, Khieu V, Muth S, Marti H, Vounatsou P, Odermatt P. Strongyloides stercoralis: Global Distribution and Risk Factors. PLoS Negl Trop Dis. 2013;7:e2288.
2. Krolleycki AJ, Lammie P, Jacobson J, Gabrielli AF, Levecke B, Socías E, Arias LM, Sosa N, Abraham D, Cimino R, Echaúz A, Crudo F, Vercruysse J, Albonico M. A public health response against Strongyloides stercoralis: time to look at soil-transmitted helminthiasis in full. PLoS Negl Trop Dis. 2013;7:e2165.
3. WHO. Working to overcome the global impact of neglected tropical diseases - Summarry. Wkly Epidemiol Rec. 2011;86:113–20.
4. Vadlamudi RS, Chi DS, Krishnaswamy G. Intestinal strongyloidiasis and hyperinfection syndrome. Clin Mol Allergy. 2006;48.
5. Viney ME, Lok JB. Strongyloides spp. WormBook. 2007;23:1-15. Review. PMID: 18050499.
6. Reese JJ, Siracusa MC, Scott AL. Innate immune responses to lung-stage helminth infection induce alternatively activated alveolar macrophages. Infect Immun. 2006;74:4970–81.
7. Fardet L, Genéreau T, Poirot JL, Guidet B, Kettaneh A, Cabane J. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect. 2007;54:18–27.
8. Feely NM, Waghorn DJ, Dexter T, Gallen I, Chiodini P. Strongyloides stercoralis hyperinfection: difficulties in diagnosis and treatment. Anaesthesia. 2010;65:296–301.
9. Suputtamongkol Y, Premasathian N, Bhumimuang K, Waywa D, Nilganuwong S, Thanachaiya S, Rattanatheerakul R, Nattaiyoussevorn C, Tantichaiyapruk A, Phummer K, van der Werf TS. Numerous cases of strongyloidiasis and hyperinfection syndrome in patients with diabetes mellitus. Am J Trop Med Hyg. 2013;89:529–34.
10. Sumpradit N, Pongubumkul W, Wongsriphun P, Suputtamongkol Y, Prasansakul P. Mortality of Strongyloidiasis in Diabetic Patients. J Trop Dis. 2010;100:96–8.
11. Hays R, Esterman A, McDermott R. Type 2 Diabetes Mellitus Is Associated with Higher Mortality from Strongyloides hyperinfection: A Population-Based Study. J Infect. 2007;54:18–27.
13. Speich B, Ali SM, Arne SM, Bogoch II, Alles R, Huwyler J, Albionico M, Hattendorf J, Utzinger J, Keiser J. Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled trial. Lancet Infect Dis. 2015;15:777–84.

14. Vercauteren J, Albionico M, Behnke JM, Kotze AC, Pichard RK, McCarthy JS, Montresor A, Levecke B. Is anthelmintic resistance a concern for the control of human soil-transmitted helminths? Int J Parasitol Drugs Resist. 2011;1:14–27.

15. Osei-Atwinebowa MI, Awadzi K, Attah SK, Boakye RA, Gyapong JO, Pichard RK. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis. 2011;5:e998.

16. Bourquinat C, Kamgno J, Boussinesq M, Mackenzie CD, Pichard RK, Geary TG. Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event. Am J Trop Med Hyg. 2010;83:28–32.

17. del Olmo E, Molina-Salinas GM, Escarceca R, Alves M, López-Pérez JL, Hernández-Pando R, Saíd-Fernández S, Feliciano AS. Simple dihydropyrophosphine analogues with potent activity against MDR-Mycobacterium tuberculosis. Bioorg Med Chem Lett. 2009;19:5764–8.

18. Howarth JL, Lloyd DG. Simple 1,2-aminoalcohols as strain-specific antimalarial agents. J Antimicrob Chemother. 2000;46:625–8.

19. del Olmo E, Alves M, López JL, Inchausti A, Yaluff G, Rojas De Arias A, San Feliciano A. Leishmanicidal activity of some aliphatic diamines and amino-alcohols. Bioorg Med Chem Lett. 2002;12:659–62.

20. del Olmo E, Díaz-González R, Escarceca R, Carvalho L, Busto LA, Navarro M, Feliciano AS. Diamine and aminoalcohol derivatives active against Trypanosoma brucei. Bioorg Med Chem Lett. 2012;22:440–3.

21. Legarda-Ceballos AL, del Olmo E, López-Abán J, Escarcena R, Carvalho L, Busto LA, Navarro M, Feliciano AS. Antimonial activity of long chain diamines and aminoalcohols. Molecules. 2015;20:15344–8.

22. Giordani RB, Araujo DP, Duarte M, Zuanazzi JA, Tasca T, De Almeida MV. Anti-protozoal activity of diamine derivatives. Biochem Pharmacol. 2011;82:560–73.

23. Dieria M, del Olmo E, Barboza B, García-Cadenas AE, López-Pérez JL, Andújar S, Enriz D, Zacchina S, San Feliciano A. Synthesis, bioevaluation and structural study of substituted phthalazin-1(2H)-ones acting as antifungal agents. Molecules. 2013;18:3479–501.

24. Fernandes FS, Rezende Junior CO, Fernandes TS, da Silveira LS, Rezende CA, De Almeida MV, de Paula RG, Rodrigues V, Da Silva Filho AA, Couri MR. Anthelmintic effects of alkylated diamines and amino alcohols against Schistosoma mansoni. Biomed Res Int. 2013;2013:783490.

25. Sánchez-Blanco A, Rodríguez-Matellán AG, Reis-Sobreiro M, Sáenz-Narciso B, Cabello J, Mohler WA, Molinelli F. Caenohabditis elegans as a platform to study the mechanism of action of synthetic antitumor lipids. Cell Cycle. 2014;13:3375–89.

26. Giordani RB, Araujo DP, Duarte M, Zuanazzi JA, Tasca T, De Almeida MV. Antiproliferative activity of aminosterols. Bioorg Med Chem Lett. 2002;12:659–62.

27. Yepes E, Varela-M RE, López-Abán J, Dávila El H, Mollinedo F, Muro A. In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine. PLoS One. 2014;9:e109431.

28. Reis EF, Castro SB, Alves CC, Oliveira EE, Correa TA, Almeida MV, Ferreira AP. Lipophilic amino alcohols reduce carragenan-induced paw edema and anti-OVA DTH in BALB/c mice. Int Immunopharmacol. 2013;13:772–82.

29. Nishizaki T, Kanno T, Tsuchiya A, Kaku Y, Shimizu T, Tanaka A. 1-(1,2-Di-2- methoxyphenylamino) ethylaminol-3-(naphthalene-1-yl)oxy-propan-2-ol may be a promising anticancer drug. Molecules. 2014;19:21462–72.

30. Pontikis E, Hadjipavlou-Litina D, Patsilinakos A, Tran TM, Manson CM. Pteridine-2,4-diamine derivatives as radical scavengers and inhibitors of lipoygenase that can possess anti-inflammatory properties. Future Med Chem. 2015;7:1937–51.

31. Pérez-Meseguer J, del Olmo E, Alanis-Garza B, Escarceca R, Garza-González E, Salazar-Arandá R, Feliciano AS, de Torres NW. Synthesis of leubethanol derivatives and evaluation against Mycobacterium tuberculosis. Bioorg Med Chem. 2012;20:4155–63.

32. Yepes E, Varela-M RE, López-Abán J, Rojas-Caraballo M, Muro A, Mollinedo F. Inhibition of granulomatous inflammation and prophylactic treatment of schistosomiasis with a combination of edelfosine and praziquantel. PLoS Negl Trop Dis. 2015;9:e0003893.

33. Carvalho CO, Chagas AC, Cotinguiba F, Furlan M, Brito LG, Chaves FC, Stephane MP, Bizzzo HR, Amarante AF. The anthelmintic effect of plant extracts on Haemonchus contortus and Strongyloides venezuelensis. Vet Parasitol. 2012;183:260–8.

34. Varela-M RE, Villa-Pulgarin JA, Yepes E, Müller I, Modelli M, Muñoz DL, Robledo SM, Muskus CE, López-Abán J, Muro A, Vélez JD, Mollinedo F. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SBV-resistant parasites. PLoS Negl Trop Dis. 2012;6:e1612.

35. del Olmo E, Macho A, Alves M, López JL, el Barious F, Muñoz E, San Feliciano A. Long-chain aminoalcohol and diamine derivatives induce apoptosis through a caspase-3 dependent pathway. Bioorg Med Chem Lett. 2002;12:2621–6.